Frequently Asked Questions
Didn’t find what you are looking for? Fill the form and we will get back as soon as possible.
1. Hydroxychloroquine for prevention of COVID-19
Mtafiti mkuu wa hapa nchini ni Dkt Anthony Etyang: barua pepe Aetyang@kemri-wellcome.org Simu +254 722 417507
The study has been approved by regulatory authorities in Kenya and is expected to start recruitment in October 2020. Participant follow up is expected to be completed by March 2021 and results published shortly thereafter.
The study may show a benefit of using hydroxychloroquine which would save many lives around the world, or alternatively may show hydroxychloroquine prophylaxis is ineffective so trials can move on to evaluate other possible interventions.
2. ChAdOx1 nCOV-19 Vaccine Trial
FAQs for ChAdOx1 nCoV-19 Vaccine Trial (Questions brought about by the on-going vaccine roll out by MoH)
Upeanaji wa chanjo ya COVID-19 wa serikali unalenga makundi ya walengwa kwa mtindo wa awamu. Takwimu zitokanazo na majaribio yanayoendelea zitaendelea kujulisha utekelezaji wa muda mrefu wa chanjo ya COVID-19 hapa Kenya katika awamu zinazofuata.
The vaccine has been approved in very many countries across the world and is being rolled out to the general population including those with underlying conditions. As of 7th March 2021, 22,377,255 doses of at least 1 COVID-19 vaccine had been given to UK residents. This would primarily be the Oxford/Astra Zeneca Vaccine and includes individuals with underlying conditions. No safety concerns have been identified in these groups since the vaccine has been rolled out across several countries. In phase 2/3 trials in the UK, South Africa and Brazil 11,636 individuals were recruited including older adults and individuals with a range of underlying conditions (cardiovascular, respiratory and diabetes) and there were no safety concerns identified in these groups.